TY - JOUR
KW - Adult
KW - Humans
KW - Female
KW - Male
KW - Retrospective Studies
KW - Anti-Bacterial Agents/therapeutic use
KW - *Clostridioides difficile
KW - *Clostridium Infections/drug therapy/epidemiology
KW - Risk Factors
KW - recurrence
KW - Clostridioides difficile infection
KW - England
KW - Epidemiological
KW - Recur
KW - Real-world study
KW - Recurrent clostridioides difficile infection
AU - S. Ghosh
AU - A. Antunes
AU - H. Rinta-Kokko
AU - E. Chaparova
AU - S. Lay-Flurrie
AU - A. Tricotel
AU - F. Andersson
AD - College of Medicine and Health, University College Cork, Cork, Ireland; University of Birmingham, Birmingham, UK.
IQVIA, Global Database Studies, Real World Solutions, Lisbon, Portugal. Electronic address: ana.antunes@iqvia.com.
IQVIA, Global Database Studies, Real World Solutions, Espoo, Finland.
IQVIA, Real World Solutions, Sofia, Bulgaria.
IQVIA, Real World Solutions, London, UK.
IQVIA, Real World Solutions, Paris, France.
Ferring Pharmaceuticals, Copenhagen, Denmark.
AN - 38185320
BT - Int J Infect Dis
DO - 10.1016/j.ijid.2024.01.002
DP - NLM
ET - 2024/01/08
LA - eng
N1 - 1878-3511
Ghosh, Subrata
Antunes, Ana
Rinta-Kokko, Hanna
Chaparova, Elena
Lay-Flurrie, Sarah
Tricotel, Aurore
Andersson, Fredrik L
Journal Article
Canada
Int J Infect Dis. 2024 Mar;140:31-38. doi: 10.1016/j.ijid.2024.01.002. Epub 2024 Jan 5.
PY - 2024
SN - 1201-9712
SP - 31
EP - 38
T2 - Int J Infect Dis
TI - Clostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015 to 2019: The RECUR England study
VL - 140
ER -